All In Biotech

Drug Trial Radar · NCT04173650

MSC EVs in Dystrophic Epidermolysis Bullosa

Mesenchymal Stem Cell Extracellular Vesicles for the Treatment of Recessive Dystrophic Epidermolysis Bullosa Wounds

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Aug 13, 2024

Primary completion

Sep 2025

Study completion Mar 2026

Sponsor

Lead sponsor
Aegle TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, randomized, multi-center, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.

Conditions

  • Dystrophic Epidermolysis Bullosa

Interventions

  • AGLE-102Drug

    Extracellular vesicles from bone marrow derived mesenchymal stem cells - up to six topical administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent Adverse EventsTime frame: 22 weeks
  2. Wound healing improvementTime frame: 10 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • USC /Norris Comprehensive Cancer Center University of Southern California

    Los Angeles, California · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.